Structure Therapeutics’ once-daily oral drug aleniglipron cut body weight by 12.1% over 36 weeks — a convenient, needle-free take on the blockbuster GLP-1 class.
Sobi gains commercial rights to lacutamab, a first-in-class antibody for cutaneous T-cell lymphoma now in a Phase 3 confirmatory trial and heading for accelerated approval.
The multi-modality site — making small molecules, biologics and antibody-drug conjugates — is part of BMS’s $40 billion U.S. push amid tariffs and reshoring.
The deal adds ABS-1230, an oral drug for KCNT1-related epilepsy that has no approved treatment — Jazz’s second epilepsy acquisition in a year.
Vanderbilt and TGen researchers used spatial transcriptomics on biopsy tissue to expose molecular variation within the same rejection grades — and flag who won’t respond to standard therapy.
A 12-week randomized study in adults with overweight found three daily servings of full-fat dairy didn’t harm cholesterol or body composition — but it was short and industry-funded.
The Nav1.8-inhibitor developer priced at the top of its range to fund a Phase 3-ready pain drug meant to rival Vertex’s Journavx, as biotech IPOs keep rolling.
Reported delays in delivering Nexviazyme — an enzyme therapy for a rare, progressive disease — follow an FDA warning letter over a Sanofi manufacturing site.
In 340,000 UK adults, low-to-moderate wine drinking was tied to lower heart-death risk while beer and spirits were tied to higher — but it’s observational, not proof.
At very high intravenous doses, vitamin C flips from antioxidant to pro-oxidant, generating a compound that preferentially damages stressed cancer cells. It’s still experimental.
Mapping brain tissue from donors aged 20 to 95, researchers saw the hippocampus’s immune cells transform in midlife — a possible link between aging and dementia.
Nagoya University researchers found it’s not the complement protein C3 in the blood that matters, but the C3 produced at the tumor — and it helps immunotherapy work.